A Phase I Study of Bevacizumab, Everolimus, and Panitumumab in Advanced Solid Tumors

PURPOSE: Preclinical data suggests concurrent inhibition of VEGF, mTOR and EGFR pathways may augment anti-tumor and anti-angiogenic effects compared to inhibition of each pathway alone. This study evaluated the maximum tolerated dose /recommended phase II dose and safety and tolerability of bevacizu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Vlahovic, Gordana, Meadows, Kellen L., Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Riedel, Richard F., Zafar, S. Yousuf, Alvarez-Secord, Angeles, Gockerman, Jon, Starodub, Alexander N., Ready, Neal E., Anderson, Elizabeth L., Bendell, Johanna C., Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086794/
https://ncbi.nlm.nih.gov/pubmed/22638798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1889-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados